The present invention relates to a fixed-
dose combination (FDC) comprising
dutasteride and
minoxidil and a formulation thereof. More specifically, the present invention relates to a pharmaceutical complex composition comprising, as active ingredients,
dutasteride, which reduces the production of
dihydrotestosterone (DHT) by inhibiting type 1 and type 2 5α-reductases, and
minoxidil, which extends the
growth phase of hair follicles and promotes
hair growth, wherein
dutasteride may be included in a range of about 0.1 mg to 5 mg and
minoxidil in a range of about 0.5 mg to 5 mg. According to one embodiment of the present invention, the composite composition may additionally include about 1 mg to 10 mg of
biotin, thereby simultaneously providing the
dihydrotestosterone (DHT) production
inhibitory effect of dutasteride and the
hair growth-promoting effect of minoxidil, as well as the
keratin synthesis-promoting effect of
biotin, which can further improve hair thickness, strength, and the formation of healthy hair. In addition, the composite composition of the present invention is manufactured as a single fixed-
dose combination (FDC), which can reduce the inconvenience associated with taking individual drugs separately or splitting tablets for low-
dose administration, and can improve accurate dosage administration, convenience of administration, and long-term
medication adherence. The composition of the present invention can be manufactured in various formulations, including oral formulations such as tablets, film-
coated tablets, capsules, soft capsules, granules, or powders, as well as
immediate release, sustained release,
dual release,
bilayer tablets, and multilayer tablets. The composite composition of the present invention can be applied to the prevention or treatment of androgenetic alopecia, female pattern
hair loss, telogen effluvium, and other
hair loss diseases, and can simultaneously provide effects of inhibiting
hair loss progression, promoting
hair growth, and strengthening hair. Furthermore, the present invention has high industrial applicability in the
pharmaceutical industry by providing a novel fixed-dose composite composition and its formulation that includes both a dual agent (dutasteride and minoxidil) and a triple agent (dutasteride, minoxidil, and
biotin).